Active Biotech has been granted a patent for a method of treating ocular inflammatory diseases, such as uveitis or conjunctivitis, using periodic administration of laquinimod or a pharmaceutically acceptable salt. The patent also covers the treatment of autoimmune disease-associated ocular inflammation. The method does not apply to subjects with Crohn’s disease. GlobalData’s report on Active Biotech gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Active Biotech, cancer treatment biomarkers was a key innovation area identified from patents. Active Biotech's grant share as of June 2023 was 1%. Grant share is based on the ratio of number of grants to total number of patents.
A recently granted patent (Publication Number: US11654140B2) describes a method for treating ocular inflammatory diseases, specifically uveitis, using the compound laquinimod or a pharmaceutically acceptable salt thereof. The method involves periodically administering a therapeutically effective amount of laquinimod to the subject, who does not have Crohn's disease.
The therapeutically effective amount of laquinimod is capable of reducing symptoms of the ocular inflammatory disease, inducing a clinical response, inducing or maintaining clinical remission, inhibiting disease progression and complications, reducing intraocular inflammation, and reducing retina tissue destruction. The uveitis can be of various types, including anterior, intermediate, posterior, or diffuse uveitis.
Laquinimod or its pharmaceutically acceptable salt can be administered in the form of a liquid or a gel, with a concentration ranging from 5-100 mg/ml solution. In particular, a concentration of 10-15 mg/ml solution is preferred. The therapeutically effective amount of laquinimod per administration ranges from 0.05-4.0 mg, with a preferred range of 0.05-2.0 mg. A specific dosage of 0.1 mg or 0.5 mg per administration can also be used. The minimum daily dosage of laquinimod or its salt is at least 0.2 mg/day.
The periodic administration of laquinimod can be done once per day, and it can be administered orally or ocularly. The pharmaceutically acceptable salt of laquinimod mentioned in the patent is laquinimod sodium. The method is applicable to human subjects.
Overall, this patent provides a method for effectively treating ocular inflammatory diseases, specifically uveitis, using laquinimod or its pharmaceutically acceptable salt. The method offers various benefits, including symptom reduction, clinical response induction, disease progression inhibition, and tissue destruction reduction. The patent also specifies preferred concentrations and dosages for administration, as well as the mode of administration.
To know more about GlobalData’s detailed insights on Active Biotech, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
